7 terminated, 4 completed, 1 active not recruiting, 1 withdrawn. 11 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Terminated 5, Completed 4, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 7 | Terminated 4, Completed 2, Withdrawn 1 |
Follow birinapant: new trials by email Literature Review of birinapant trials Research Report on birinapant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars) - Solid Tumor, Colorectal Cancer | Phase 1 | Terminated | IGM Biosciences, Inc. | 272 | 2020-09-23 | 2025-03-28 |
| Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma Biopsy Procedure, Birinapant, Computed Tomography - Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2019-09-25 | 2026-08-03 |
| Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) Birinapant, Carboplatin, Laboratory Biomarker Analysis - High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2018-08-01 | 2025-05-13 | |
| Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors Birinapant, Pembrolizumab - Solid Tumors | Phase 1 / Phase 2 | Terminated | Medivir | 34 | 2017-08-04 | 2021-01-14 |
| Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B Antiviral Therapy (tenofovir or entecavir), Birinapant, Placebo (for birinapant) - Hepatitis B | Phase 1 | Terminated | TetraLogic Pharmaceuticals | 7 | 2014-11-01 | 2016-02-05 |
| Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL birinapant, Azacitidine, Placebo - Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML) | Phase 2 | Terminated | TetraLogic Pharmaceuticals | 118 | 2014-06-01 | 2016-10-20 |
| Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer Birinapant, Conatumumab - Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer | Phase 1 | Completed | TetraLogic Pharmaceuticals | 27 | 2013-11-01 | 2016-01-14 |
| Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy Birinapant, 5-Azacitidine - Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | TetraLogic Pharmaceuticals | 21 | 2013-06-01 | 2016-04-21 |
| Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer Birinapant (TL32711) - Epithelial Ovarian Cancer, Peritoneal Neoplasms | Phase 2 | Terminated | National Cancer Institute (NCI) | 11 | 2012-08-15 | 2017-05-30 |
| Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors Smac mimetic TL32711, gemcitabine hydrochloride, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Terminated | Roswell Park Cancer Institute | 21 | 2012-04-01 | 2022-08-15 |
| A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia Birinapant - Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | Abramson Cancer Center at Penn Medicine | 27 | 2011-11-01 | 2021-06-24 |
| Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors Birinapant - Cancer | Phase 1 / Phase 2 | Completed | TetraLogic Pharmaceuticals | 176 | 2010-10-01 | 2016-05-30 |
| Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma Birinapant (TL32711) - Cancer | Phase 1 | Completed | TetraLogic Pharmaceuticals | 50 | 2009-11-01 | 2016-03-03 |
Fallopian Tube Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Neoplasms (2) · Recurrence (2) · Chondrosarcoma (1) · Colorectal Neoplasms (1) · Hepatitis B (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Peritoneal Neoplasms (1)
TetraLogic Pharmaceuticals (6) · National Cancer Institute (NCI) (2) · Abramson Cancer Center at Penn Medicine (1) · IGM Biosciences, Inc. (1) · Jonsson Comprehensive Cancer Center (1) · Medivir (1) · Roswell Park Cancer Institute (1)
United States (12) · Australia (3) · Spain (2) · France (1) · Germany (1) · South Korea (1)
Alex Adjei, MD, PhD (2) · Lainie P Martin, MD (2) · Ravi Amaravadi, MD (2) · Christina M Annunziata, M.D. (1) · Eric Humke, MD, PhD (1) · Gautam Borthakur, MD (1) · John N Nemunaitis, MD (1) · Kyriakos P Papadopoulos, MD (1) · Noelle Frey, MD (1) · Patricia LoRusso, DO (1) · Sanaz Memarzadeh (1) · Vassiliki Saloura (1) · Wen Wee Ma (1) · Zdenka Segota, MD (1)
2014 (1)